CDM 050Alternative Names: CDM050
Latest Information Update: 01 Mar 2017
At a glance
- Originator Kao Corporation
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Skin disorders
Most Recent Events
- 26 Jan 2017 Clinical trials in Skin disorders in North America (Topical) (UMIN000025668)
- 16 Jan 2017 Kao Corporation plans a clinical trial for skin disorders in North America (UMIN000025668)
- 01 Jan 2017 Preclinical trials in Skin disorders in Japan (Topical) before January 2017 (UMIN000025668)